Characterization of treatment failure in efficacy trials of drugs against <em>Plasmodium vivax</em> by genotyping neutral and drug... (Publications)
Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typi
Can farm milk consumption prevent allergic diseases? (Publications)
Cow's milk is an important part of human diet and a source of food allergy for some individuals. Medical guidance strongly discourages consumption of raw milk because of the known health risk associat
Helminth infections, morbidity indicators, and schistosomiasis treatment history in three villages, Dongting Lake region, P.R. China (Publications)
In order to estimate the public health impact of helminth infections, and to provide baseline data for interventions, parasitological and morbidity surveys were conducted among inhabitants of three vi
Biobanking for epidemiological research and public health (Publications)
Almost all healthcare systems are currently facing fundamental challenges. New ways of organizing these systems based on novel knowledge and stakeholders' different needs are required to meet these ch
Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites (Publications)
Human African trypanosomiasis (HAT), caused by the protozoan parasite Trypanosoma brucei spp., is a major health problem in sub-Saharan Africa. New drugs are urgently required for the disease. Selecti
Structure-activity study of pentamidine analogues as antiprotozoal agents (Publications)
Diamidine 1 (pentamidine) and 65 analogues (2-66) have been tested for in vitro antiprotozoal activities against Trypanosoma brucei rhodesiense, Plasmodium falciparum, and Leishmania donovani, and for
Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a... (Publications)
BACKGROUND: The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been